Abstract: Rechargeable dehumidifier including inside it the components it consists of, with the possibility that none of them project outward so that it can have an outward appearance without projections, as well as being simple to manufacture, comprising a casing with at least one first opening and open on the top, which configures a first internal cavity, a first lid arranged on top of the casing, provided in the first cavity with a container that in turn comprises a body open on the top that configures a second cavity, a second lid provided on top of the body and having at least one second opening; on top of the second lid may be provided a desiccant agent such that the water absorbed by it is collected in the body when it falls by gravity.

Abstract: Rechargeable dehumidifier including inside it the components it consists of, with the possibility that none of them project outward so that it can have an outward appearance without projections, as well as being simple to manufacture, comprising a casing with at least one first opening and open on the top, which configures a first internal cavity, a first lid arranged on top of the casing, provided in the first cavity with a container that in turn comprises a body open on the top that configures a second cavity, a second lid provided on top of the body and having at least one second opening; on top of the second lid may be provided a desiccant agent such that the water absorbed by it is collected in the body when it falls by gravity.

Abstract: Humidity absorber that does not drip, occupies a small space and can be reused, usable both outdoors and indoors, comprising a bag that houses a sack that in turn contains a hygroscopic material, the bag being made of a 3D spacer material configuring a single cavity that houses the sack, provided with an opening having closing means, the opening allowing the sack to be introduced in the cavity or removed from the same such that the sack with hygroscopic material can be replaced to reuse the absorber.

Abstract: The present invention relates to new histamine H3 (H3) receptor subtype selective ligands of the general formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and the use of these compounds as medicaments for treatment and/or prevention of conditions which require modulation of H3 receptors. The invention also cover the combinations of a compound of the general formula (I) and an acetylcholinesterase inhibitor.

Abstract: Humidity absorber that does not drip, occupies a small space and can be reused, usable both outdoors and indoors, comprising a bag that houses a sack that in turn contains a hygroscopic material, the bag being made of a 3D spacer material configuring a single cavity that houses the sack, provided with an opening having closing means, the opening allowing the sack to be introduced in the cavity or removed from the same such that the sack with hygroscopic material can be replaced to reuse the absorber.

Abstract: The present invention relates to new histamine H3 (H3) receptor subtype selective ligands of the general formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and the use of these compounds as medicaments for treatment and/or prevention of conditions which require modulation of H3 receptors. The invention also cover the combinations of a compound of the general formula (I) and an acetylcholinesterase inhibitor.

Abstract: The invention relates to a modified human CYP4B1 protein and a nucleic acid encoding for the modified human CYP4B1 protein. The invention further relates to an expression vector comprising a nucleic acid encoding for a modified human CYP4B1 protein, as well as to a cell comprising a modified CYP4B1 protein. In addition, the invention relates to a modified human CYP4B1 protein for use in treating transplantation induced graft-versus-host-disease (GvHD), and to 4-ipomeanol (4-IPO) for use in killing a cell.

Abstract: The present invention relates to new dopamine D3 and D2 ligands of formula (I): wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of conditions which requires modulation of dopamine receptors.

Abstract: The present invention relates to metabolites of(thio)-carbamoyl cyclohexane derivatives, particularly, metabolites of trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing the same and to their use in the treatment and/or prevention of a conditions which requires modulation of dopamine receptors.

Abstract: The present invention relates to new phenylsulfamoyl benzamide derivatives of formula (I) wherein R1-R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, to pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

Abstract: The present invention relates to new sulfonamide derivatives of formula (I) wherein R1-R8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these same compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

Abstract: The present invention relates to new sulfonamide derivatives of formula (I), wherein R1-R8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these same compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

Abstract: The present invention relates to new phenanthridine derivatives of formula (I), wherein the variables are as defined in the specification, to processes for producing the same, to pharmacological compositions containing the same and to their use in therapy or prevention of painful and inflammatory processes.